ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brais, M. P.
Right arrow Articles by Keon, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brais, M. P.
Right arrow Articles by Keon, W. J.

The Annals of Thoracic Surgery, Vol 39, 105-111, Copyright © 1985 by The Society of Thoracic Surgeons


ARTICLES

Ionescu-Shiley pericardial xenografts: follow-up of up to 6 years

MP Brais, JP Bedard, W Goldstein, A Koshal and WJ Keon

The results of valve replacement with the Ionescu-Shiley pericardial xenograft compare favorably with results obtained with other bioprostheses. From March, 1977, to July, 1983, 497 Ionescu-Shiley pericardial valves were implanted in 463 patients at the University of Ottawa Heart Institute. There were 292 patients who had aortic valve replacement (AVR), 140 with mitral valve replacement (MVR), 28 with double valve replacement, and 3 with triple valve replacement. The survivors were followed regularly. Actuarial analysis of late results indicates an expected survival of 71% at 6 years for patients who underwent AVR and 72% at 3 years for patients who had MVR. The only valve-related deaths were due to endocarditis, which occurred at a rate of 3.9% per patient-year for aortic valves and 0.6% per patient-year for mitral valves. Despite a low usage of formal anticoagulation, embolic complications occurred at a rate of 1.4% per patient-year for aortic valves and 4.0% per patient-year for mitral valves. Five valves were removed for intrinsic failure after 36 to 72 months of follow-up. New York Heart Association Functional Class improved an average of 1.28 classes per patient.


This article has been cited by other articles:


Home page
J. Thorac. Cardiovasc. Surg.Home page
D. M. Cosgrove, B. W. Lytle, P. C. Taylor, M. T. Camacho, R. W. Stewart, P. M. McCarthy, D. P. Miller, M. R. Piedmonte, and F. D. Loop
The Carpentier-Edwards pericardial aortic valve: Ten-year results
J. Thorac. Cardiovasc. Surg., September 1, 1995; 110(3): 651 - 662.
[Abstract] [Full Text]


Home page
J Biomater ApplHome page
G. Golomb
Controlled Release of Diphosphonates from Synthetic Polymers to Inhibit Calcification
J Biomater Appl, January 1, 1987; 2(2): 266 - 289.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1985 by The Society of Thoracic Surgeons.